

Folic Acid, Pyridoxine, and Cyanocobalamin Combination Treatment and Age-Related Macular Degeneration in Women

The Women's Antioxidant and Folic Acid Cardiovascular Study

William G. Christen, ScD; Robert J. Glynn, ScD; Emily Y. Chew, MD; Christine M. Albert, MD; JoAnn E. Manson, MD

Background: Observational epidemiologic studies indicate a direct association between homocysteine concentration in the blood and the risk of age-related macular degeneration (AMD), but randomized trial data to examine the effect of therapy to lower homocysteine levels in AMD are lacking. Our objective was to examine the incidence of AMD in a trial of combined folic acid, pyridoxine hydrochloride (vitamin B₆), and cyanocobalamin (vitamin B₁₂) therapy.

Methods: We conducted a randomized, double-blind, placebo-controlled trial including 5442 female health care professionals 40 years or older with preexisting cardiovascular disease or 3 or more cardiovascular disease risk factors. A total of 5205 of these women did not have a diagnosis of AMD at baseline and were included in this analysis. Participants were randomly assigned to receive a combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d) or placebo. Our main outcome measures included total AMD, defined as a self-report documented by medical record evidence of an initial diagnosis after randomization,

and visually significant AMD, defined as confirmed incident AMD with visual acuity of 20/30 or worse attributable to this condition.

Results: After an average of 7.3 years of treatment and follow-up, there were 55 cases of AMD in the combination treatment group and 82 in the placebo group (relative risk, 0.66; 95% confidence interval, 0.47-0.93 [$P = .02$]). For visually significant AMD, there were 26 cases in the combination treatment group and 44 in the placebo group (relative risk, 0.59; 95% confidence interval, 0.36-0.95 [$P = .03$]).


Conclusions: These randomized trial data from a large cohort of women at high risk of cardiovascular disease indicate that daily supplementation with folic acid, pyridoxine, and cyanocobalamin may reduce the risk of AMD.

Trial Registration: clinicaltrials.gov Identifier NCT00000161

Arch Intern Med. 2009;169(4):335-341

Author Affiliations: Divisions of Preventive Medicine (Drs Christen, Glynn, Albert, and Manson) and Cardiovascular Medicine (Dr Albert), Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and Departments of Biostatistics (Dr Glynn) and Epidemiology (Dr Manson), Harvard School of Public Health, Boston, Massachusetts; and National Eye Institute, Bethesda, Maryland (Dr Chew).

AGE-RELATED MACULAR DEGENERATION (AMD) is the leading cause of severe irreversible vision loss in older Americans.¹ An estimated 1.75 million individuals in the United States have advanced AMD (ie, geographic atrophy and neovascular AMD), which accounts for most cases of severe vision loss.¹ An additional 7.3 million persons have early AMD,¹ which is usually associated with little or no vision loss,^{2,3} but increases the risk of developing advanced

 **CME available online at www.jamaarchivescme.com and questions on page 329**

AMD.^{4,5} Current treatment options are limited to patients with late-stage, neovascular AMD⁶⁻¹⁰ or intermediate AMD.¹¹ For the large population with early or no AMD, there is no method of disease prevention other than avoidance of cigarette smok-

ing.¹²⁻¹⁴ Accordingly, the National Eye Institute has designated the development of new treatments for AMD as an important program goal for vision research.¹⁵

Recent cross-sectional¹⁶⁻¹⁸ and case-control¹⁹⁻²³ studies indicate a direct association between homocysteine concentration in the blood and the risk of AMD, suggesting that homocysteine may be a modifiable risk factor for AMD. Homocysteine is an intermediary amino acid formed during the metabolism of methionine, an essential amino acid derived from protein.²⁴ Hyperhomocysteinemia, defined as a plasma homocysteine concentration of more than 2.0 mg/L (to convert to micromoles per liter, multiply by 7.397),^{25,26} induces vascular endothelial dysfunction²⁷⁻²⁹ and is considered to be an independent risk factor for atherosclerosis and cardiovascular disease (CVD).^{30,31} Treatment with folic acid, pyridoxine hydrochloride (vitamin B₆), and cyanocobalamin (vitamin B₁₂) has been shown to reduce homocysteine levels in intervention studies³² and to reverse endothelial dys-




Figure 1. Enrollment and randomization scheme for the folic acid, pyridoxine, and cyanocobalamin component of the Women's Antioxidant and Folic Acid Cardiovascular Study. Combination treatment indicates folic acid (2.5 mg/d), pyridoxine hydrochloride (vitamin B₆) (50 mg/d), and cyanocobalamin (vitamin B₁₂) (1 mg/d). Of the 8171 women who were randomized, 5442 were willing and eligible to participate in the arm that tested combination treatment vs placebo.

function independent of the effect of lowering homocysteine levels.^{33,34} However, trials of therapy to lower homocysteine levels among persons with preexisting vascular disease provide little support for a benefit of supplemental folic acid and B vitamins in reducing cardiovascular events.³⁵ Nonetheless, given the recent evidence supporting a link between homocysteine and AMD and other data suggesting an etiologic role for atherosclerosis and endothelial dysfunction in AMD,³⁶⁻³⁹ it is reasonable to propose that lowering homocysteine levels with folic acid and B vitamin supplements may help to decrease the risk of AMD. At present, no previous data exist from large randomized trials to examine this hypothesis.

In this report, we present the results for AMD from the Women's Antioxidant and Folic Acid Cardiovascular Study (WAFACS), a randomized trial that evaluated whether combined treatment with folic acid, pyridoxine, and cyanocobalamin could prevent cardiovascular events among women at high risk of CVD.

METHODS

STUDY DESIGN

WAFACS was a randomized, double-blind, placebo-controlled trial that evaluated whether a combination of folic acid, pyridoxine, and cyanocobalamin could reduce cardiovascular events among

women with preexisting CVD or with 3 or more coronary risk factors.⁴⁰⁻⁴² The WAFACS began in 1998, when the treatment arm consisting of folic acid, pyridoxine, and cyanocobalamin was added to the ongoing Women's Antioxidant Cardiovascular Study (WACS), a 2 × 2 × 2 factorial trial of 8171 women at high risk of CVD who were randomized from June 1995 through October 1996 to receive vitamin E, ascorbic acid (vitamin C), beta carotene, or placebos (**Figure 1**). From August 1997 through January 1998, all 8171 women participating in the WACS were sent invitations and consent forms for participation in the folic acid/pyridoxine/cyanocobalamin (combination treatment) arm of the trial. Of the total cohort, 5442 women were willing and eligible to participate in this arm of the trial and were willing to forego the use of vitamin B supplements or multivitamins with greater than the recommended daily allowance of folic acid, vitamin B₆, and vitamin B₁₂. In April 1998, these women were randomized in a retained factorial design to a daily combination of folic acid (2.5 mg/d), pyridoxine hydrochloride (50 mg/d), and cyanocobalamin (1 mg/d). Of these women, 5205 did not have a diagnosis of AMD at baseline and underwent these analyses, including 2607 in the combination treatment group and 2598 in the placebo group. Informed consent was obtained from all participants, and the research protocol was reviewed and approved by the institutional review board at Brigham and Women's Hospital.

Annual questionnaires were sent to all participants to monitor their adherence to the pill regimen and the occurrence of any relevant events including AMD. The pill regimen was completed on July 31, 2005, at which point morbidity and mortality follow-up was 92.6% complete. End point ascertainment for

AMD ended in November 2005. Overall, approximately 84.0% of women reported taking at least two-thirds of their study pills during the course of the study, with no significant difference between the active and placebo groups.

ASCERTAINMENT AND DEFINITION OF END POINTS

Women who reported a diagnosis of AMD on the baseline questionnaire were excluded. Information on new diagnoses of AMD was requested on annual questionnaires. Participants were asked, "Since your last questionnaire, have you had any of the following?" with response options including "macular degeneration right eye" and "macular degeneration left eye." If yes, participants were requested to provide the month and year of the diagnosis and to complete a consent form granting permission to examine medical records pertaining to the diagnosis. Ophthalmologists and optometrists were contacted by mail and requested to complete an AMD questionnaire that asked about the date of the initial diagnosis, the best-corrected visual acuity at the time of diagnosis, and the date when best-corrected visual acuity reached 20/30 or worse (if different from the date of initial diagnosis). Information was also requested about the signs of AMD observed (ie, drusen, retinal pigment epithelium [RPE] hypopigmentation or hyperpigmentation, geographic atrophy, RPE detachment, subretinal neovascular membrane, or disciform scar) when visual acuity was first noted to be 20/30 or worse, and the date when exudative neovascular disease, if present, was first noted (defined by the presence of RPE detachment, subretinal neovascular membrane, or disciform scar). Ophthalmologists and optometrists were also asked whether there were other ocular abnormalities that could explain or contribute to the vision loss and, if so, whether the AMD by itself was significant enough to cause the best-corrected visual acuity to be reduced to 20/30 or worse. As an alternative, they could provide the requested information by supplying photocopies of the relevant medical records. Medical records were obtained for 94.0% of participants reporting AMD.

The following 2 end points were defined: (1) total AMD, defined as a self-report confirmed by medical record evidence of an initial diagnosis after randomization but before July 31, 2005, and (2) visually significant AMD, with the same definition as total AMD but with best-corrected visual acuity loss to 20/30 or worse attributable to AMD.

DATA ANALYSIS

Cox proportional hazards regression was used to estimate the relative risk (RR) of AMD among those assigned to receive the combination treatment compared with those assigned to receive placebo after adjustment for age (in years) at baseline and randomized assignments to ascorbic acid, vitamin E, and beta carotene treatment.⁴³ Models were also fit separately within the prespecified age groups of 40 to 54 years, 55 to 64 years, and 65 years or older. The proportionality assumption throughout the follow-up period was tested by including an interaction term of folic acid/pyridoxine/cyanocobalamin with the logarithm of time in the Cox models. For each RR, we also calculated the 95% confidence interval (CI) and 2-sided *P* value.

We also analyzed the subgroup data by categories of baseline variables that are possible risk factors for AMD. We explored possible modification of any effect of the combination treatment by using interaction terms between the subgroup indicators and folic acid/pyridoxine/cyanocobalamin, with testing for trend when subgroup categories were ordinal.

Individuals rather than eyes were the unit of analysis because eyes were not examined independently, and participants

Table 1. Baseline Characteristics in Randomized Combination and Placebo Treatment Groups

Characteristic	Treatment Group, % of Participants	
	Combination ^a (n=2607)	Placebo (n=2598)
Mean age, y	62.6	62.6
40-54	22.0	22.1
55-64	37.1	36.3
≥65	40.9	41.7
Cigarette smoking		
Current	11.4	12.2
Past only	43.6	45.0
Never	45.0	42.7
Alcohol use		
Daily	33.2	32.7
Weekly	12.2	12.4
Rarely/never	54.6	54.9
BMI, mean (SD)	30.6 (6.7)	30.7 (6.7)
<25.0, %	22.5	20.3
25.0-29.9, %	27.9	29.5
≥30.0, %	49.6	50.2
Hypertension ^b	86.6	85.7
Elevated cholesterol level ^c	77.6	78.8
Diabetes mellitus	21.3	21.6
Prior cardiovascular disease	64.4	62.6
Menopausal status		
Premenopausal	6.3	6.5
Postmenopausal/current HT	48.9	49.3
Postmenopausal/no HT	42.3	42.2
Dubious/unclear	2.5	2.0
Current use of multivitamin supplements ^d	22.5	23.1
Aspirin use in past mo ^e	62.4	62.1

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HT, hormone therapy.

^aIndicates folic acid (2.5 mg/d), pyridoxine hydrochloride (vitamin B₆) (50 mg/d), and cyanocobalamin (vitamin B₁₂) (1 mg/d).

^bIndicates self-reported systolic blood pressure of at least 140 mm Hg, diastolic blood pressure of at least 90 mm Hg, self-reported physician-diagnosed hypertension, or reported treatment with medication for hypertension.

^cIndicates self-reported high cholesterol levels, cholesterol level of at least 240 mg/dL (to convert to millimoles per liter, multiply by 0.0259), self-reported physician-diagnosed high cholesterol levels, or reported treatment with medication to lower cholesterol levels.

^dIndicates any multivitamin use in the past month.

^eIndicates aspirin use at least 4 times per month.

were classified according to the status of the worse eye as defined by disease severity.^{44,45} When the worse eye was excluded because of visual acuity loss attributed to other ocular abnormalities, the fellow eye was considered for classification.

RESULTS

The baseline characteristics of participants in the combination treatment and placebo groups are shown in **Table 1**. As expected, characteristics were equally distributed between the 2 treatment groups.

During an average of 7.3 years of treatment and follow-up, a total of 137 cases of AMD were documented, including 70 cases of visually significant AMD. Most of the visually significant cases were characterized by some combination of drusen and RPE changes at the time vision was first noted to be 20/30 or worse, reflecting an early




Figure 2. Cumulative incidence rates of confirmed age-related macular degeneration (AMD) (A) and visually significant AMD (B). Combination treatment indicates folic acid (2.5 mg/d), pyridoxine hydrochloride (vitamin B₆) (50 mg/d), and cyanocobalamin (vitamin B₁₂) (1 mg/d).

stage of AMD development, as shown in the following tabulation:

Signs of AMD	No. (%) of Participants
Drusen only	13 (19)
RPE changes only	18 (26)
Drusen and RPE changes	19 (27)
Geographic atrophy	2 (3)
Exudative changes ^a	17 (24)
Information missing	1 (1)
Total	70 (100)

^aIncludes RPE detachment, subretinal neovascular membrane, and disciform scar.

For the end point of total AMD, there were 55 cases in the combination treatment group and 82 in the placebo group (RR [adjusted for age and ascorbic acid (vitamin C), vitamin E, and beta carotene treatment assignment], 0.66; 95% CI, 0.47-0.93 [$P = .02$]). For visually significant AMD, there were 26 cases in the combination treatment group and 44 in the placebo group (RR, 0.59; 95% CI, 0.36-0.95 [$P = .03$]). Relative risks did not vary significantly over the 3 age groups for either end point (P interaction, each $> .2$).

Cumulative incidence rates of total AMD and visually significant AMD according to the year of follow-up are shown in **Figure 2**. A beneficial effect of the combination treatment on total AMD began to emerge at approximately 2 years of treatment and follow-up and persisted throughout the trial (Figure 2A). For visually significant AMD, the curves appeared to diverge later in the trial, at approximately 4 years (Figure 2B). For both end points, the rate differences appeared to increase with longer follow-up. During the first 3 years of follow-up, the RRs were 0.87 (95% CI, 0.54-1.42 [$P = .59$]) for total AMD and 0.84 (95% CI, 0.39-1.78 [$P = .65$]) for visually significant AMD. During the remaining 4.3 years of follow-up, the RRs were 0.72 (95% CI, 0.44-1.18 [$P = .19$]) for total AMD and 0.52 (95% CI, 0.27-0.98 [$P = .04$]) for visually significant AMD. Tests of proportionality throughout the follow-up period, however, indicated that the proportionality assumption for treatment was not violated

for either end point (total AMD, $P = .47$; visually significant AMD, $P = .42$).

There was no evidence that the effect of combination treatment on either AMD end point was modified by any AMD risk factor considered. The results for visually significant AMD are shown in **Table 2**.

COMMENT

To our knowledge, this is the first randomized trial to investigate supplemental use of folic acid and B vitamins in the prevention of AMD. The results, based on an average of 7.3 years of treatment and follow-up of women at increased risk of CVD, indicate that those assigned to active treatment had a statistically significant 35% to 40% decreased risk of AMD. The beneficial effect of treatment began to emerge at approximately 2 years of follow-up and persisted throughout the trial.

Support for the hypothesis that therapy consisting of folic acid and B vitamin supplements could lower the risk of AMD has derived largely from observational evidence of a direct association between the homocysteine level in the blood and risk of AMD¹⁶⁻²³ and from the demonstration in intervention studies that treatment with folic acid and B vitamin supplements could lower homocysteine levels.³² Further support has been provided by laboratory evidence that the damaging sequelae of elevated homocysteine levels (eg, endothelial dysfunction,^{27,29,46} impaired vascular reactivity,^{28,47,48} and promotion of inflammatory processes leading to atherosclerosis⁴⁹⁻⁵¹) thought to underlie the increased risk of vascular disease may also contribute to the pathophysiological features of AMD.³⁶⁻³⁹ The trial findings reported herein are the strongest evidence to date in support of a possible beneficial effect of folic acid and B vitamin supplements in AMD prevention. Moreover, because these findings apply to the early stages of AMD development (most cases were characterized by a combination of drusen and RPE changes) in persons with-

Table 2. Risk for Diagnosis of Visually Significant AMD According to Combination Treatment Assignment, as Modified by Other Risk Factors

Characteristic	No. With AMD/No. of Participants		RR ^b (95% CI)	P Value ^c
	Combination Treatment ^a (n=2607)	Placebo (n=2598)		
Age, y				.24
40-54	0/574	2/573	NA	
55-64	4/968	9/942	0.42 (0.13-1.38)	
≥65	22/1065	33/1083	0.67 (0.39-1.15)	
Cigarette smoking				.47
Current	2/296	7/318	0.32 (0.07-1.55)	
Past only	12/1137	19/1170	0.61 (0.30-1.26)	
Never	12/1174	18/1110	0.66 (0.32-1.37)	
Alcohol use				.54
Daily	8/866	17/850	0.45 (0.20-1.05)	
Weekly	7/318	5/321	1.33 (0.42-4.21)	
Rarely/never	11/1423	22/1427	0.50 (0.24-1.04)	
BMI, %				.76
<25.0	8/586	11/528	0.63 (0.25-1.58)	
25.0-29.9	9/727	16/767	0.62 (0.27-1.40)	
≥30.0	9/1294	17/1303	0.53 (0.24-1.19)	
Hypertension				.16
Yes	20/2258	39/2227	0.50 (0.29-0.86)	
No	6/349	5/371	1.21 (0.37-3.99)	
Hyperlipidemia				.97
Yes	20/2023	34/2046	0.59 (0.34-1.02)	
No	6/584	10/552	0.70 (0.25-1.97)	
Diabetes mellitus				.19
Yes	1/554	7/560	0.14 (0.02-1.12)	
No	25/2053	37/2038	0.65 (0.39-1.09)	
Prior CVD				.57
Yes	21/1678	33/1627	0.64 (0.37-1.09)	
No	5/929	11/971	0.45 (0.16-1.30)	
Current HT use ^d				.92
Yes	12/1274	21/1280	0.60 (0.29-1.22)	
No	14/1102	23/1096	0.57 (0.29-1.11)	
Current use of multivitamin supplements ^e				.92
Yes	6/587	9/599	0.72 (0.26-2.03)	
No	20/2020	35/1997	0.56 (0.32-0.97)	
Aspirin use in past mo ^f				.30
Yes	18/1626	36/1614	0.51 (0.29-0.90)	
No	8/980	8/984	0.91 (0.34-2.44)	

Abbreviations: AMD, age-related macular degeneration; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CI, confidence interval; CVD, cardiovascular disease; HT, hormone therapy; NA, not applicable; RR, replacement risk.

^aIndicates folic acid (2.5 mg/d), pyridoxine hydrochloride (vitamin B₆) (50 mg/d), and cyanocobalamin (vitamin B₁₂) (1 mg/d).

^bAdjusted for age and vitamin C, vitamin E, and beta carotene treatment assignment.

^cCalculated by means of a test of interaction.

^dAnalysis was restricted to postmenopausal women.

^eInformation on current use of multivitamins was missing for 2 participants in the placebo group.

^fInformation on aspirin use in the past month was missing for 1 participant in the combination treatment group.

out a prior diagnosis of AMD, they appear to represent the first identified means, other than avoidance of cigarette smoking, of reducing risks of AMD in persons at usual risk. From a public health perspective, this is particularly important because persons with early AMD are at increased risk of developing advanced AMD, the leading cause of severe, irreversible vision loss in older Americans.

Whether the reduced risk of AMD observed in WAFACS is due to lowering of homocysteine levels by the combination treatment or is independent of lowered homocysteine levels is an important question to be investigated. We examined the impact of the intervention on homocysteine levels in a substudy of 300 WAFACS participants (150 in each treatment group) who had blood samples col-

lected at study entry in 1993 through 1995, and again at study completion in 2005. Details of the substudy are presented elsewhere.⁴² In short, the geometric mean plasma homocysteine level was decreased by 18.5% (95% CI, 12.5%-24.1% [$P < .001$]) in the active arm compared with the placebo arm, a difference of 0.31 mg/L (95% CI, 0.21-0.40 mg/L). These substudy findings indicate that the reduced risk of AMD we observed in the combination treatment group may have been due, at least in part, to lowering of homocysteine levels. However, a treatment benefit independent of lowering homocysteine levels is also possible. Plausible mechanisms include a direct antioxidant effect of folic acid and B vitamin supplements and enhancement of endothelial nitric oxide levels in the cho-

roidal vasculature, with an associated increase in vascular reactivity.⁵²⁻⁵⁴ Further study is required to distinguish between these and other possibilities.

Our findings for AMD are in sharp contrast to the null findings for CVD observed in the WAFACS⁴² and other completed trials to lower homocysteine levels in persons with preexisting vascular disease, despite substantial lowering of homocysteine concentrations by study treatment in those trials.⁵⁵⁻⁶³ Although our findings could be due to chance and need to be confirmed in other populations, it may be worthwhile to consider whether the discordant findings for AMD and CVD reflect important differences between the choroidal and systemic vasculature with respect to responsiveness to the lowering of homocysteine levels. Age-related macular degeneration is a disease that likely involves damage to the small vessels of the choroid,^{66,67} and some evidence suggests that homocysteine may be a more potent risk factor for small-vessel disease than for large vessel disease.⁶⁸⁻⁷⁰ If so, small-vessel diseases such as AMD and perhaps some subtypes of stroke (eg, lacunar brain infarcts and cerebral white matter lesions) may be more amenable to benefit from lowering homocysteine concentrations. A recent meta-analysis of completed trials of therapy to lower homocysteine levels indicated that folic acid supplementation had little effect on CVD (pooled RR, 0.95; 95% CI, 0.88-1.03) or coronary heart disease (1.04; 0.92-1.17), but was associated with a nonsignificant 14% reduced risk for total stroke (0.86; 0.71-1.04).³⁵ Further detailed analyses of etiologic subtypes of stroke in these trials may suggest a beneficial effect of folic acid supplementation that is observable primarily in diseases of the small vessels.

In summary, daily supplementation with folic acid, pyridoxine, and cyanocobalamin during an average of 7.3 years of follow-up reduced the risk of AMD in women at increased risk of vascular disease. Because there are currently no recognized means to prevent the early stages of AMD development other than avoidance of cigarette smoking, these findings could have important clinical and public health implications and need to be confirmed in other populations of men and women.

Accepted for Publication: September 26, 2008.

Correspondence: William G. Christen, ScD, Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 900 Commonwealth Ave E, Boston, MA 02215-1204 (wchristen@rics.bwh.harvard.edu).

Author Contributions: Dr Christen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. *Study concept and design:* Manson. *Acquisition of data:* Christen and Manson. *Analysis and interpretation of data:* Christen, Glynn, Chew, Albert, and Manson. *Drafting of the manuscript:* Christen. *Critical revision of the manuscript for important intellectual content:* Glynn, Chew, Albert, and Manson. *Statistical analysis:* Glynn. *Obtained funding:* Christen and Manson. *Administrative, technical, and material support:* Christen, Albert, and Manson. *Study supervision:* Christen and Manson.

Financial Disclosure: Dr Christen has received research funding support from the National Institutes of Health, Harvard University (Clinical Nutrition Research Cen-

ter), and DSM Nutritional Products, Inc (Roche). Dr Glynn has received support from grants to the Brigham and Women's Hospital from AstraZeneca, Bristol-Meyers Squibb Company, Merck and Company, Inc, and Novartis. Dr Manson has received research funding support from the National Institutes of Health and research support for study pills and/or packaging from BASF Corporation and Cognis Corporation.

Funding/Support: This study was supported by grants HL 46959 from the National Heart, Lung, and Blood Institute and EY 06633 from the National Eye Institute. Vitamin E and its placebo were provided by Cognis Corporation. All other agents and their placebos were provided by BASF Corporation.

Role of the Sponsor: Cognis Corporation and BASF Corporation did not participate in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.

Additional Contributions: We are indebted to the 5442 participants in the Women's Antioxidant and Folic Acid Cardiovascular Study for their dedicated and conscientious collaboration; to the entire staff of the Women's Antioxidant and Folic Acid Cardiovascular Study, including Marilyn Chown, MPH, Elaine Zaharris, BA, Ellie Danielson, MIA, Margarete Haubourg, Felicia Zangi, Shamikhah Curry, Tony Laurinaitis, Geneva McNair, Philomena Quinn, Harriet Samuelson, MA, Ara Sarkissian, MM, Jean MacFadyen, BA, and Martin Van Denburgh, BA.

REFERENCES

1. Friedman DS, O'Colmain BJ, Munoz B, et al; Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. *Arch Ophthalmol*. 2004;122(4):564-572.
2. Klein R, Wang Q, Klein BE, Moss SE, Meuer SM. The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity. *Invest Ophthalmol Vis Sci*. 1995;36(1):182-191.
3. Hogg RE, Chakravarthy U. Visual function and dysfunction in early and late age-related maculopathy. *Prog Retin Eye Res*. 2006;25(3):249-276.
4. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam Eye Study. *Ophthalmology*. 2002;109(10):1767-1779.
5. Ferris FL, Davis MD, Clemons TE, et al; Age-Related Eye Disease Study (AREDS) Research Group. A simplified severity scale for age-related macular degeneration: AREDS report No. 18. *Arch Ophthalmol*. 2005;123(11):1570-1574.
6. Bressler NM; Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials—TAP report 2. *Arch Ophthalmol*. 2001;119(2):198-207.
7. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization: Verteporfin in Photodynamic Therapy report 2. *Am J Ophthalmol*. 2001;131(5):541-560.
8. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. *N Engl J Med*. 2004;351(27):2805-2816.
9. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. *Ophthalmology*. 2005;112(6):1035-1047.
10. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med*. 2006;355(14):1419-1431.
11. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. *Arch Ophthalmol*. 2001;119(10):1417-1436.
12. Christen WG, Glynn RJ, Manson JE, Ajani UA, Buring JE. A prospective study of

- cigarette smoking and risk of age-related macular degeneration in men. *JAMA*. 1996;276(14):1147-1151.
13. Seddon JM, Willett WC, Speizer FE, Hankinson SE. A prospective study of cigarette smoking and age-related macular degeneration in women. *JAMA*. 1996; 276(14):1141-1146.
 14. Klein R, Klein BE, Moss SE. Relation of smoking to the incidence of age-related maculopathy: the Beaver Dam Eye Study. *Am J Epidemiol*. 1998;147(2):103-110.
 15. National Eye Institute. National plan for eye and vision research: Retinal Diseases Program. Updated November 2004. http://www.nei.nih.gov/strategicplanning/np_retinal.asp. Accessed November 10, 2006.
 16. Heuberger RA, Fisher AI, Jacques PF, et al. Relation of blood homocysteine and its nutritional determinants to age-related maculopathy in the Third National Health and Nutrition Examination Survey. *Am J Clin Nutr*. 2002;76(4):897-902.
 17. Axer-Siegel R, Bourla D, Ehrlich R, et al. Association of neovascular age-related macular degeneration and hyperhomocysteinemia. *Am J Ophthalmol*. 2004; 137(1):84-89.
 18. Rochtchina E, Wang JJ, Flood VM, Mitchell P. Elevated serum homocysteine, low serum vitamin B₁₂, folate, and age-related macular degeneration: the Blue Mountains Eye Study. *Am J Ophthalmol*. 2007;143(2):344-346.
 19. Nowak M, Swietochowska E, Wielkoszynski T, et al. Homocysteine, vitamin B₁₂, and folic acid in age-related macular degeneration. *Eur J Ophthalmol*. 2005; 15(6):764-767.
 20. Vine AK, Stader J, Branham K, Musch DC, Swaroop A. Biomarkers of cardiovascular disease as risk factors for age-related macular degeneration. *Ophthalmology*. 2005;112(12):2076-2080.
 21. Coral K, Raman R, Rathi S, et al. Plasma homocysteine and total thiol content in patients with exudative age-related macular degeneration. *Eye*. 2006;20(2): 203-207.
 22. Kamburoglu G, Gumus K, Kadayifcilar S, Eldem B. Plasma homocysteine, vitamin B₁₂ and folate levels in age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol*. 2006;244(5):565-569.
 23. Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of plasma homocysteine and risk of age-related macular degeneration. *Am J Ophthalmol*. 2006;141 (1):201-203.
 24. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. *Annu Rev Med*. 1998;49:31-62.
 25. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. *Clin Chem*. 1993;39(9):1764-1779.
 26. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med*. 1998; 338(15):1042-1050.
 27. Chambers JC, Obeid OA, Kooner JS. Physiological increments in plasma homocysteine induce vascular endothelial dysfunction in normal human subjects. *Arterioscler Thromb Vasc Biol*. 1999;19(12):2922-2927.
 28. Domagala TB, Undas A, Libura M, Szczeklik A. Pathogenesis of vascular disease in hyperhomocysteinemia. *J Cardiovasc Risk*. 1998;5(4):239-247.
 29. McDowell IF, Lang D. Homocysteine and endothelial dysfunction: a link with cardiovascular disease. *J Nutr*. 2000;130(2S)(suppl):369S-372S.
 30. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. *JAMA*. 2002;288(16):2015-2022.
 31. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ*. 2002;325(7374):1202-1208.
 32. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. *Am J Clin Nutr*. 2005;82(4):806-812.
 33. Woo KS, Choock P, Lolini YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocysteinemia. *J Am Coll Cardiol*. 1999;34(7):2002-2006.
 34. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-Methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. *Circulation*. 1998;97(3):237-241.
 35. Bazzano LA, Reynolds K, Holder KN, He J. Effect of folic acid supplementation on risk of cardiovascular diseases. *JAMA*. 2006;296(22):2720-2726.
 36. Vingerling JR, Dielemans I, Bots ML, Hofman A, Grobbee DE, de Jong PT. Age-related macular degeneration is associated with atherosclerosis: the Rotterdam Study. *Am J Epidemiol*. 1995;142(4):404-409.
 37. Snow KK, Seddon JM. Do age-related macular degeneration and cardiovascular disease share common antecedents? *Ophthalmic Epidemiol*. 1999;6(2):125-143.
 38. Friedman E. The role of the atherosclerotic process in the pathogenesis of age-related macular degeneration. *Am J Ophthalmol*. 2000;130(5):658-663.
 39. Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. *Ophthalmology*. 2001;108(4):705-710.
 40. Bassuk SS, Albert CM, Cook NR, et al. The Women's Antioxidant Cardiovascular Study. *J Womens Health (Larchmt)*. 2004;13(1):99-117.
 41. Cook NR, Albert CM, Gaziano JM, et al. A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study. *Arch Intern Med*. 2007;167(15):1610-1618.
 42. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. *JAMA*. 2008;299(17):2027-2036.
 43. Cox DR. Regression models and life tables. *J R Stat Soc (B)*. 1972;34:187-220.
 44. Ederer F. Shall we count numbers of eyes or numbers of subjects? *Arch Ophthalmol*. 1973;89(1):1-2.
 45. Glynn RJ, Rosner B. Accounting for the correlation between fellow eyes in regression analysis. *Arch Ophthalmol*. 1992;110(3):381-387.
 46. Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. *JAMA*. 1999; 281(22):2113-2118.
 47. Upchurch GR, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. *J Biol Chem*. 1997;272(27):17012-17017.
 48. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. *Circulation*. 2001;104(21):2569-2575.
 49. Silverman MD, Tumuluri RJ, Davis M, Lopez G, Rosenbaum JT, Lelkes PI. Homocysteine upregulates vascular cell adhesion molecule-1 expression in cultured human aortic endothelial cells and enhances monocyte adhesion. *Arterioscler Thromb Vasc Biol*. 2002;22(4):587-592.
 50. Tsai JC, Perrella MA, Yoshizumi M, et al. Promotion of vascular smooth muscle cell growth by homocysteine. *Proc Natl Acad Sci U S A*. 1994;91(14):6369-6373.
 51. Dudman NP, Temple SE, Guo XW, Fu W, Perry MA. Homocysteine enhances neutrophil-endothelial interactions in both cultured human cells and rats in vivo. *Circ Res*. 1999;84(4):409-416.
 52. Hayden MR, Tyagi SC. Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atherosclerosis: the pleiotropic effects of folate supplementation. *Nutr J*. 2004;3:4.
 53. Doshi SN, McDowell IF, Moat SJ, et al. Folic acid improves endothelial function in coronary artery disease via mechanisms largely independent of homocysteine lowering. *Circulation*. 2002;105(1):22-26.
 54. Moat SJ, Lang D, McDowell IF, et al. Folate, homocysteine, endothelial function and cardiovascular disease. *J Nutr Biochem*. 2004;15(2):64-79.
 55. Lonn E, Yusuf S, Arnold MJ, et al; Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. *N Engl J Med*. 2006;354(15):1567-1577.
 56. Bona KH, Njølstad I, Ueland PM, et al; NORVIT Trial Investigators. Homocysteine lowering and cardiovascular events after acute myocardial infarction. *N Engl J Med*. 2006;354(15):1578-1588.
 57. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. *JAMA*. 2004;291(5):565-575.
 58. Liem A, Reynierse-Buitemwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid. *Heart*. 2005;91(9):1213-1214.
 59. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B₁₂, and vitamin B₆ on clinical outcome after percutaneous coronary intervention: the Swiss Heart Study: a randomized controlled trial. *JAMA*. 2002;288(8):973-979.
 60. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. *N Engl J Med*. 2004;350(26):2673-2681.
 61. Righetti M, Ferrario GM, Milani S, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. *Med Sci Monit*. 2003;9(4):PI19-PI24.
 62. Liem AH, van Boven AJ, Veeger NJ, et al; Folic Acid on Risk Diminishment After Acute Myocardial Infarction Study Group. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomised pilot trial. *Int J Cardiol*. 2004;93(2-3):175-179.
 63. Wrona EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. *J Am Soc Nephrol*. 2004;15(2):420-426.
 64. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. *Blood Purif*. 2006;24(4):379-386.
 65. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure. *J Am Coll Cardiol*. 2006;47(6):1108-1116.
 66. Grunwald JE, Hariprasad S, DuPont J, et al. Foveolar choroidal blood flow in age-related macular degeneration. *Invest Ophthalmol Vis Sci*. 1998;39(2):385-390.
 67. Ciulla TA, Harris A, Kagemann L, et al. Choroidal perfusion perturbations in non-neovascular age related macular degeneration. *Br J Ophthalmol*. 2002;86(2): 209-213.
 68. Evers S, Koch HG, Grottemeyer KH, Lange B, Deufel T, Ringelstein EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. *Arch Neurol*. 1997;54(10):1276-1282.
 69. Fassbender K, Mielke O, Bertsch T, Nafe B, Fröschen S, Hennerici M. Homocysteine in cerebral macroangiography and microangiopathy. *Lancet*. 1999;353 (9164):1586-1587.
 70. Hassan A, Hunt BJ, O'Sullivan M, et al. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. *Brain*. 2004;127(pt 1):212-219.